Abstract: Some implementations disclosed herein measure an effect of content exposure (e.g., lift attributable to ad campaign content) by comparing exposed and unexposed conversion (e.g., visit) rates. The measurement processing is distributed between the computing systems used/controlled by different entities: a processing entity and a conversion data collection entity (e.g., a selling entity) so that identifier-level conversion data (e.g., user-level conversion data, device-level conversion data, household-level conversion data, etc.) does not need to leave the conversion data collection entity system(s).

Abstract: Some implementations disclosed herein enable matching identifiers across multiple sources. This may involve adding a unique attribute (e.g., anonymous unique homomorphic identifiers) and/or using randomization to enable comparing data from multiple sources, while also maintaining data privacy. In one example, matches across multiple sources are identified, for example, identifying that there are 100 user identifiers that are in private data sets of three different sources. Such matching may be used to enable private, multi-touch attribution. In another example, techniques are used to determine that data maintained by one source is not also within other sources (e.g., identifying that there are 200 user identifiers that are in data from a first source but not in data from a second source and not in data from a third source. Such determinations may be used to generate control group data that does not match data from other sources.

Abstract: The invention relates to a medical implant (1) that is adapted to repair or close defect (D), in particular an opening in a ventricular, atrial, or septal wall (W). The medical implant (1) may, in particular, be a patch. It comprises an adhesive composition (6). It further comprises two states, wherein in the first state, the medical implant (1) can be deployed to an implant site while the adhesive composition (6) is inactive. It can be brought into a second state by an activation mechanism. The adhesive composition (6), in the second state, is curable by a curing mechanism.

Abstract: Some implementations disclosed herein enable matching identifiers across multiple sources. This may involve adding a unique attribute (e.g., anonymous unique homomorphic identifiers) and/or using randomization to enable comparing data from multiple sources, while also maintaining data privacy. In one example, matches across multiple sources are identified, for example, identifying that there are 100 user identifiers that are in private data sets of three different sources. Such matching may be used to enable private, multi-touch attribution. In another example, techniques are used to determine that data maintained by one source is not also within other sources (e.g., identifying that there are 200 user identifiers that are in data from a first source but not in data from a second source and not in data from a third source. Such determinations may be used to generate control group data that does not match data from other sources.

Abstract: Provided are compositions comprising a hydrogel formed from a cyclodextrin-modified branched polyethyleneimine and an adamantane-modified, eight-arm polyethyelene glycol. The hydrogel may contain an active agent, and can provide sustained release the active agent. Beneficial delivery characteristics may result from electrostatic or lipophilic interactions between the active agent and the hydrogel. Delivery of valproic acid from the present compositions can provide treatment following surgical resection of glioblastoma brain tumors.

Abstract: Provided are polysaccharide compositions capable of controllable hydrolytic degradation and suitable for controlled release of therapeutic agents. Also provided are methods for synthesizing such compositions and a variety of applications in which the compositions may be used.

Abstract: The invention concerns methods of delivering a hydrogel to the heart, comprising: introducing a hydrogel composition into a subject, said hydrogel comprising components mixed prior to introduction; the introducing being performed such that the hydrogel composition resides between the epicardium and the pericardium of the subject. In some embodiments, the injection is performed using a syringe or catheter.

Abstract: Provided is a multi-fiber system that undergoes new chemical bonds in response to mechanical manipulation and has self-adhesive properties based on specific chemical reactions.

Abstract: Provided are polysaccharide compositions capable of controllable hydrolytic degradation and suitable for controlled release of therapeutic agents. Also provided are methods for synthesizing such compositions and a variety of applications in which the compositions may be used.

Abstract: The present disclosure is directed to methods of printing 3-D structures using supramolecular gels, and the structures that result therefrom.

Abstract: Provided are compositions comprising a hydrogel formed from a cyclodextrin-modified branched polyethyleneimine and an adamantane-modified, eight-arm polyethyelene glycol. The hydrogel may contain an active agent, and can provide sustained release the active agent. Beneficial delivery characteristics may result from electrostatic or lipophilic interactions between the active agent and the hydrogel. Delivery of valproic acid from the present compositions can provide treatment following surgical resection of glioblastoma brain tumors.

Abstract: The invention concerns compositions comprising: (i) biocompatible hydrogel, comprising a plurality of cross-linkers connecting backbone components of the hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by a matrix metalloproteinase; said inhibitor being effective as a treatment of a condition related to the presence of the matrix metalloproteinase; wherein the hydrogel encapsulates and retains the inhibitor within the intact hydrogel through non-covalent interactions; wherein the hydrogel comprises one or more of hyaluronic acid, sulfated hyaluronic acid, sulfonated hyaluronic acid, dextran, dextran sulfate, sulfonated dextran, chondroitin sulfate, heparin and heparan sulfate; (ii) pentosan polysulfate (PPS) and (iii) optionally, a therapeutic agent comprising an inhibitor of matrix metalloproteinase.

Abstract: The invention relates to compositions comprising (i) biocompatible hydrogel and (ii) one or more therapeutic agents contained within said hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme; the therapeutic agent being effective as a treatment of a condition related to the presence of the enzyme.

Abstract: The invention relates to compositions comprising (i) biocompatible hydrogel and (ii) one or more therapeutic agents contained within said hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme; the therapeutic agent being effective as a treatment of a condition related to the presence of the enzyme.

Abstract: The invention relates to compositions comprising (i) biocompatible hydrogel and (ii) one or more therapeutic agents contained within said hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme; the therapeutic agent being effective as a treatment of a condition related to the presence of the enzyme.

Abstract: The invention relates to compositions comprising (i) biocompatible hydrogel and (ii) one or more therapeutic agents contained within said hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme; the therapeutic agent being effective as a treatment of a condition related to the presence of the enzyme.

Abstract: The invention relates to compositions comprising (i) biocompatible hydrogel and (ii) one or more therapeutic agents contained within said hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme; the therapeutic agent being effective as a treatment of a condition related to the presence of the enzyme.

Abstract: The present disclosure is directed to methods of printing 3-D structures using supramolecular gels, and the structures that result therefrom.

Abstract: Disclosed herein are compositions comprising an osteoinductive Notch ligand bound to at least one biocompatible substrate. Also disclosed are methods of treating patients in need of bone tissue formation through the administration of a composition comprising an osteoinductive Notch ligand bound to at least one biocompatible substrate. Further provided are methods of treating a patient in need of bone tissue formation comprising administering to said patient a composition comprising a nucleic acid molecule encoding a notch intracellular domain (NICD). Also disclosed are kits for promoting bone tissue formation.

Abstract: Acrylate-terminated poly(beta-amino esters) are cross-linked to form materials useful in the medical as well as non-medical field. The polymeric starting material is combined with a free radical initiator, either a thermal initiator or a photoinitiator, and the mixture for cross-linking is heated or exposed to light depending on the initiator used. The resulting materials due to the hydrolysable ester bond in the polymer backbone are biodegradable under physiological conditions. These cross-linked materials are particular useful as drug delivery vehicles, tissue engineering scaffolds, and in fabricating microdevices. The materials may also be used as plastics, coating, adhesives, inks, etc. The cross-linked materials prepared exhibit a wide range of degradation times, mass loss profiles, and mechanical properties. Therefore, the properties of the material may be tuned for the desired use.